Primary biliary cirrhosis is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are symptoms of primary biliary cirrhosis, which can progress to hepatomegaly and hyperpigmentation splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.
Frequently Asked Questions
The market is segmented based on Segmentation, By Diagnosis (Imaging Tests, Blood Tests, Others), Treatment Type (Liver Transplantation, Drug Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Primary Biliary Cholangitis Market size was valued at USD 1.05 USD Billion in 2024.
The Global Primary Biliary Cholangitis Market is projected to grow at a CAGR of 10.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
